TORONTO, March 06, 2023 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, and PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA)…

Source

Previous articlePsychedelic Bulletin #132: COMPASS Pathways Amends Phase 3 Program; Stamets Stack Finally Patented; Learning from Zuranolone?
Next articleReunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference